Roche’s Basel Drug Substance site, a key player in the company’s goal to launch 20 new transformative medicines by 2030, produces a wide range of treatments, including chemically synthesized small molecules. To enhance efficiency, the site deployed digital and AI solutions that cut yield variability by 60%, halved technology transfer time, and reduced Scope 1 and 2 emissions by 31%, reinforcing its critical role in Roche’s global network.